Workflow
West Pharmaceutical(WST)
icon
Search documents
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
ZACKS· 2024-11-19 14:26
West Pharmaceutical Services, Inc. (WST) is well poised for growth, backed by the robust Proprietary Products segment and sustained strength in research and development (R&D). However, foreign exchange volatility is a concern.Shares of this Zacks Rank #3 (Hold) company have lost 12.8% year to date against the industry's 2.8% growth. The S&P 500 Index has increased 23.4% in the same time frame.West Pharmaceutical, with a market capitalization of $22.78 billion, is a leading global manufacturer, engaged in th ...
West to Participate in Upcoming Investor Conferences
Prnewswire· 2024-10-29 10:00
EXTON, Pa., Oct. 29, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following conferences: UBS Global Healthcare Conference in Rancho Pablos Verdes, California, on November 12, 2024 at 3:30 PM PST Jefferies Healthcare Conference in London, UK on Tuesday, November 19, 2024 at 1:00 PM GMT Stephens Annual Investment Conference in Nashville, TN on Thursday, November 21, 2 ...
West Pharmaceutical(WST) - 2024 Q3 - Quarterly Report
2024-10-24 20:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State ...
West Pharmaceutical(WST) - 2024 Q3 - Earnings Call Transcript
2024-10-24 19:02
West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2024 Results Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants John Sweeney - Vice President, Investor Relations Eric Green - Chairman, President and Chief Executive Officer Bernard Birkett - Senior Vice President, Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Lawrence Solow - CJS Securities Michael Ryskin - BofA Global Research David Windley - Jefferies Matthew Larew - William Blair & Company Justi ...
West Pharmaceutical(WST) - 2024 Q3 - Earnings Call Presentation
2024-10-24 17:11
Third-Quarter 2024 WST Q3 2024 Earnings 1 Third Quarter Overall Net Sales $746.9M | 0.1% Diluted Earnings Per Share: $1.85 Adjusted Diluted Earnings Per Share: $1.85 "We are pleased to report solid third quarter results. Our West team across the globe continues to execute at a high-level, motivated by our purpose of improving patient lives. A key aspect of our strategy is West's team of scientific thought leaders and technical experts who continue to drive strong partnership and close collaboration with our ...
West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend
Benzinga· 2024-10-24 17:09
On Thursday, West Pharmaceutical Services, Inc. WST reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50.The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $746.9 million, beating the consensus of $709.62 million.The Proprietary Products Segment’s sales declined by 0.2% to $601.4 million, and the organic net sales decline was 0.5%.High-value products (components and devices) represented over 75% of segment net sal ...
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
ZACKS· 2024-10-24 16:10
West Pharmaceutical Services, Inc. (WST) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.85, which beat the Zacks Consensus Estimate of $1.51 by 22.5%. However, the bottom line decreased 14.4% year over year.The adjustments include expenses related to the amortization of acquisition-related intangible assets.GAAP EPS for the quarter was $1.85, down 13.6% year over year.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Revenues in DetailWest Pharmaceutical registere ...
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates
ZACKS· 2024-10-24 12:11
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $2.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.52%. A quarter ago, it was expected that this medical device company would post earnings of $1.77 per share when it actually produced earnings of $1.52, delivering a surprise of -14.12%.Over the last ...
West Pharmaceutical(WST) - 2024 Q3 - Quarterly Results
2024-10-24 11:50
Exhibit 99.1 https://files.reportify.cc/media/production/WST4135fcd308fa West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares FourthQuarter 2024 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 24, 2024 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (comparisons to prior-year period) • Net sales of $746 ...
West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend
Prnewswire· 2024-10-24 10:00
- Conference Call Scheduled for 9 a.m. EDT Today -EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend.Third-Quarter 2024 Summary (comparisons to prior-year period)Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%.Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.Adjusted-diluted EPS of $1.85, compared to $2.1 ...